Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury

European Heart Journal

Volumn 34, Issue 22, 2013, Pages 1681-1690

  Liang, Hongliang ^a   Hou, Huiyuan ^a   Yi, Wei ^a   Yang, Guodong ^b   Gu, Chunhu ^a   Lau, Wayne Bond ^c   Gao, Erhe ^c   Ma, Xinliang ^c   Lu, Zifan ^b   Wei, Xufeng ^a   Pei, Jianming ^b   Yi, Dinghua ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Mesenchymal stem cells; Myocardial infarction; Paracrine; Pigment epithelium derived factor

Indexed keywords

5' NUCLEOTIDASE; ADENOVIRUS VECTOR; BETA1 INTEGRIN; CD11B ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; HERMES ANTIGEN; PIGMENT EPITHELIUM DERIVED FACTOR; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; IMMUNOFLUORESCENCE TEST; MACROPHAGE; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; PARACRINE; PIGMENT EPITHELIUM-DERIVED FACTOR;

AGING; ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE PROTEINS; FIBROSIS; GRAFT SURVIVAL; HEART VENTRICLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOFIBROBLASTS; NERVE GROWTH FACTORS; SERPINS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878881266     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr131     Document Type: Article

References (32)

1. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-2988.
2. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008;453:322-329.
3. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
4. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008;26: 2201-2210.
5. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009;20:419-427.
6. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-1219.
7. Salem HK, Thiemermann C. Mesenchymal Stromal Cells-Current Understanding and Clinical Status. Stem Cells 2010;28:585-596.
8. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009;217: 318-324.
9. Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD et al. PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Biochem 2008;104: 1793-1802.
10. Chiellini C, Cochet O, Negroni L, Samson M, Poggi M, Ailhaud G et al. Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol 2008;9:26.
11. Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2009;13: 1295-1302.
12. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008;102:1319-1330.
13. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM et al.Jacobsen SE, Fleischmann BK. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007;110:1362-1369.
14. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 2010;107:1445-1453.
15. Becerra SP. Focus on Molecules: Pigment epithelium-derived factor (PEDF). Exp Eye Res 2006;82:739-740.
16. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004;23:561-577.
17. Ho TC, Yang YC, Chen SL, Kuo PC, Sytwu HK, Cheng HC et al. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. Mol Immunol 2008;45:898-909.
18. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007;170:2159-2170.
19. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA 2009;106:14022-14027.
20. Kawaguchi T, Yamagishi S, Itou M, Okuda K, Sumie S, Kuromatsu R et al. Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. Am J Pathol 2010;176:168-176.
21. Hou HY, Liang HL, Wang YS, Zhang ZX, Wang BR, Shi YY et al. A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions. Mol Ther 2010;18:1837-1845.
22. Pina AL, Kubitza M, Brawanski A, Tombran-Tink J, Kloth S. Expression of pigment-epithelium-derived factor during kidney development and aging. Cell Tissue Res 2007;329:329-338.
23. Francis MK, Appel S, Meyer C, Balin SJ, Balin AK, Cristofalo VJ. Loss of EPC-1/PEDF expression during skin aging in vivo. J Invest Dermatol 2004;122:1096-1105.
24. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685.
25. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007;581:3961-3966.
26. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006;47:3912-3918.
27. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al. CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-889.
28. Hatzistergos KE, Quevedo H, Oskouei BN, Hu QH, Feigenbaum GS, Margitich IS et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010;107:913-922.
29. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007;21:3197-3207.
30. Cheng ZK, Ou LL, Zhou X, Li F, Jia XH, Zhang YG et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571-579.
31. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-2286.
32. Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science 2009;324:1666-1669.